HOME > Articles >

Korean J Gastroenterol  <  Volume 73(1); 2019 <  Articles

Korean J Gastroenterol 2019; 73(1): 26-34  https://doi.org/10.4166/kjg.2019.73.1.26
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy
Sung Eun Kim*, Ji Hun Roh1*, Moo In Park , Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung and Jae Joon Heo
Department of Internal Medicine, Kosin University College of Medicine; Department of Internal Medicine, Dong-eui Medical Center1, Busan, Korea
Correspondence to: Moo In Park, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, Korea. Tel: +82-51-990-6719, Fax: +82-51-990-5055, E-mail: mipark@kosinmed.or.kr, ORCID: https://orcid.org/0000-0003-2071-6957
*The first two authors contributed equally to this work as co-first authors of this paper.
Received: October 1, 2018; Revised: December 5, 2018; Accepted: December 19, 2019; Published online: January 25, 2019.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background/Aims: Both bismuth-containing quadruple therapy and moxifloxacin-containing triple therapy have been suggested as second-line eradication therapy for Helicobacter pylori (H. pylori) infection. We aimed to evaluate the efficacy of 14-day moxifloxacin-containing triple therapy (14-EAM) in second-line H. pylori eradication in comparison to 7-day bismuth-containing quadruple therapy (7-RBMT).
Methods:
From January 2011 to December 2015, a total of 569 patients who failed to respond to first-line triple therapy and who subsequently received second-line 7-RBMT or 14-EAM were retrospectively enrolled. The eradication rates were identified using per-protocol (PP) analysis. H. pylori eradication was confirmed by a 13C-urea breath test (UBiT-IR300®; Otsuka Electronics, Co., Ltd., Osaka, Japan) or a rapid urease test (CLOtest®; Delta West, Bentley, Australia) at least 4 weeks after completion of eradication therapy.
Results: A total of 487 and 82 patients received 7-RBMT and 14-EAM, respectively. PP eradication rates were 93.6% (366/391; 95% CI, 91.0-95.9%) with 7-RBMT and 73.8% (48/65; 95% CI, 63.1-84.6%) with14-EAM (p<0.001). Therefore, the eradication rates with 7-RBMT were significantly higher than with 14-EAM according to the PP analysis. The adverse event rate was 17.1% (67/391) with 7-RBMT and 7.7% (5/65) with 14-EAM (p=0.065). In terms of risk factors, multivariate analysis revealed that 14-EAM (OR, 5.47; 95% CI, 2.74-10.93) was related to H. pylori eradication failure.
Conclusions: 7-RBMT may be an effective second-line therapy in patients who failed to respond to first-line triple therapy in Korea, where there is a high prevalence of H. pylori infection.
Keywords: Helicobacter pylori; Disease eradication; Bismuth tripotassium dicitrate; Moxifloxacin


This Article


Author ORCID Information

Stats or Metrics
  • View: 227
  • Download: 159

Services
Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • thomson reuters
  • pubmedcentral
  • koreamed
  • crossref
  • crossref
  • synepse
  • kofst
  • DOAJ
  • ORCID